Alphamab Oncology (HKG:9966) logged 113.9 million yuan in attributable loss for 2025, swinging from a profit of 166.3 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.
The cancer therapy developer's shares fell by more than 3% in late-morning trade on Wednesday.
Loss per share was 0.12 yuan, compared with earnings of 0.17 yuan in the prior year.
Revenue fell to 566.2 million yuan from 640.1 million yuan in 2024, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.